MediPharm Labs Corp. MEDIF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -5.83% | 1.41% | 5.60% | 14.88% | 14.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.83% | 1.41% | 5.60% | 14.88% | 14.31% |
| Cost of Revenue | -7.81% | 4.24% | 1.26% | 27.31% | 30.74% |
| Gross Profit | -1.73% | -4.32% | 15.78% | -6.52% | -9.31% |
| SG&A Expenses | -21.77% | 0.08% | -4.14% | 0.15% | 0.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 180.72% | 75.05% | 30.76% | -9.98% | 204.89% |
| Total Operating Expenses | -13.37% | 2.60% | -1.06% | 14.33% | 16.45% |
| Operating Income | 52.26% | -9.64% | 28.52% | -11.32% | -28.92% |
| Income Before Tax | 42.57% | -16.58% | 23.89% | 34.65% | 37.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.57% | -16.58% | 23.89% | 33.14% | 36.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.57% | -16.58% | 23.89% | 33.14% | 36.37% |
| EBIT | 52.26% | -9.64% | 28.52% | -11.32% | -28.92% |
| EBITDA | 62.24% | -25.08% | 25.81% | -38.94% | -75.29% |
| EPS Basic | 43.71% | -14.39% | 26.04% | 35.65% | 39.11% |
| Normalized Basic EPS | 55.91% | -5.06% | 30.97% | -11.69% | -27.40% |
| EPS Diluted | 43.71% | -14.39% | 26.04% | 35.65% | 39.11% |
| Normalized Diluted EPS | 55.91% | -5.06% | 30.97% | -11.69% | -27.40% |
| Average Basic Shares Outstanding | 2.39% | 2.43% | 2.55% | 4.12% | 4.33% |
| Average Diluted Shares Outstanding | 2.39% | 2.43% | 2.55% | 4.12% | 4.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |